The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy

Jasmohan S. Bajaj, Leroy R. Thacker, Douglas M. Heuman, Michael Fuchs, Richard K. Sterling, Arun J. Sanyal, Puneet Puri, Mohammad S. Siddiqui, Richard T. Stravitz, Iliana Bouneva, Velimir Luketic, Nicole Noble, Melanie B. White, Pamela Monteith, Ariel Unser, James B. Wade – 6 February 2013 – Minimal hepatic encephalopathy (MHE) detection is difficult because of the unavailability of short screening tools. Therefore, MHE patients can remain undiagnosed and untreated. The aim of this study was to use a Stroop smartphone application (app) (EncephalApp_Stroop) to screen for MHE.

GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I‐dependent adenylyl cyclase 8

Romina Mancinelli, Antonio Franchitto, Shannon Glaser, Fanyin Meng, Paolo Onori, Sharon DeMorrow, Heather Francis, Julie Venter, Guido Carpino, Kimberley Baker, Yuyan Han, Yoshiyuki Ueno, Eugenio Gaudio, Gianfranco Alpini – 6 February 2013 – Large, but not small, cholangiocytes (1) secrete bicarbonate by interaction with secretin receptors (SRs) through activation of cystic fibrosis transmembrane regulator (CFTR), Cl−/HCO3− (apex) anion exchanger 2 (Cl−/HCO3− AE2), and adenylyl cyclase (AC)8 (proteins regulating large biliary functions) and (2) proliferate in response to bile duct ligation

The impact of timing and prioritization on the cost‐effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

Phil McEwan, Thomas Ward, Yong Yuan, Ray Kim, Gilbert L'Italien – 6 February 2013 – Recent United States guidelines recommend one‐time birth cohort testing for hepatitis C infection in persons born between 1945 and 1965; this represents a major public health policy undertaking. The purpose of this study was to assess the role of treatment timing and prioritization on predicted cost‐effectiveness.

Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells in mice

Kei Kiyohashi, Sei Kakinuma, Akihide Kamiya, Naoya Sakamoto, Sayuri Nitta, Hideto Yamanaka, Kouhei Yoshino, Junko Fujiki, Miyako Murakawa, Akiko Kusano‐Kitazume, Hiromichi Shimizu, Ryuichi Okamoto, Seishin Azuma, Mina Nakagawa, Yasuhiro Asahina, Naoki Tanimizu, Akira Kikuchi, Hiromitsu Nakauchi, Mamoru Watanabe – 5 February 2013 – The molecular mechanisms regulating differentiation of fetal hepatic stem/progenitor cells, called hepatoblasts, which play pivotal roles in liver development, remain obscure.

Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma

Jiaxin Xie, Yuwei Zhang, Qi Zhang, Yifang Han, Jianhua Yin, Rui Pu, Qiuxia Shen, Wei Lu, Yan Du, Jun Zhao, Xue Han, Hongwei Zhang, Guangwen Cao – 5 February 2013 – Hepatitis B virus (HBV) mutations and signal transducer and activator of transcription 3 (STAT3) activation are closely associated with hepatocellular carcinoma (HCC). However, single nucleotide polymorphisms (SNPs) of STAT3 have not been implicated in HCC susceptibility. This study was designed to evaluate the effect of STAT3 SNPs and their interactions with HBV mutations on HCC risk.

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B. Martins, Leland J. Yee, John F. Flaherty, Kathryn M. Kitrinos, Vinod K. Rustgi, Patrick Marcellin – 30 January 2013 – We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.

Subscribe to